View ValuationNIOX Group 향후 성장Future 기준 점검 2/6NIOX Group (는) 각각 연간 17.4% 및 6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 11.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 12.5% 로 예상됩니다.핵심 정보17.4%이익 성장률11.87%EPS 성장률Medical Equipment 이익 성장13.3%매출 성장률6.0%향후 자기자본이익률12.50%애널리스트 커버리지Low마지막 업데이트21 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesDeclared Dividend • May 20Dividend of UK£0.015 announcedShareholders will receive a dividend of UK£0.015. Ex-date: 21st May 2026 Payment date: 22nd June 2026 Dividend yield will be 2.3%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is not adequately covered by earnings (92% earnings payout ratio). However, it is well covered by cash flows (46% cash payout ratio). The dividend has increased by an average of 24% per year over the past 2 years and payments have been stable during that time. The company's earnings per share (EPS) would need to grow by 1.9% to bring the payout ratio under control. EPS is expected to grow by 40% over the next 3 years, which is sufficient to bring the dividend into a sustainable range.공시 • Apr 22NIOX Group Plc, Annual General Meeting, May 21, 2026NIOX Group Plc, Annual General Meeting, May 21, 2026. Location: the companys registered office magdalen centre, 1 robert robinson ave, the oxford science park, england, ox4 4ga, oxford United Kingdom공시 • Mar 25Niox Group plc Recommends Final Dividend for the Year Ended 31 December 2025NIOX Group Plc announced that the Board recommended the payment of a final dividend of 1.55 pence per fully paid ordinary share (2024: 1.25 pence). The aggregate amount of the proposed dividend expected to be paid after the reporting date, out of retained earnings at 31 December 2025, but not recognized as a liability at year end is £6.5 million (2024: £5.0 million).공시 • Mar 20NIOX Group Plc to Report Fiscal Year 2025 Results on Mar 24, 2026NIOX Group Plc announced that they will report fiscal year 2025 results on Mar 24, 2026공시 • Jul 08NIOX Group Plc to Report First Half, 2025 Results on Sep 30, 2025NIOX Group Plc announced that they will report first half, 2025 results on Sep 30, 2025공시 • Apr 03Niox Group plc Recommends Final Dividend for the Year Ended December 31, 2024NIOX Group Plc recommended final dividend of 1.25 pence per share in respect of the year ended December 31 2024.공시 • Mar 21An unknown funds managed by Keensight Capital made a proposal to acquire NIOX Group Plc (AIM:NIOX) for approximately £320 million.An unknown funds managed by Keensight Capital made a proposal to acquire NIOX Group Plc (AIM:NIOX) for approximately £320 million on February 20, 2025. As on March 6, 2025, The Board of NIOX Group received a revised proposal from Keensight Capital on behalf of funds managed or advised by it ("Keensight") regarding a possible cash offer to acquire the entire issued and to be issued ordinary share capital of NIOX (the "Proposal") at an offer price of £0.81 per NIOX share, the Proposal follows a previous unsolicited approach by Keensight to acquire NIOX on February 20, 2025 at an offer price of £0.78 per NIOX share. The Proposal is subject to the satisfaction or waiver by Keensight of a number of pre-conditions, including the completion of satisfactory due diligence. Accordingly, the Board has agreed to provide Keensight with access to due diligence. Discussions with Keensight remain at a preliminary stage and, as such, there can be no certainty that any firm offer will be made for the Company by Keensight, nor as to the terms of any such offer, should one be made. Lazard & Co., Limited and Singer Capital Markets Advisory LLP acted as financial advisor to NIOX.공시 • Jan 17NIOX Group Plc, Annual General Meeting, May 14, 2025NIOX Group Plc, Annual General Meeting, May 14, 2025.공시 • Jan 16+ 1 more updateNIOX Group Plc Appoints Jonathan Emms as Chief Executive OfficerNIOX Group Plc announced Jonathan Emms, currently Chief Operating Officer, has been appointed Chief Executive Officer with immediate effect.공시 • Dec 04NIOX Group Plc to Report Fiscal Year 2024 Results on Apr 01, 2025NIOX Group Plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Apr 01, 2025Reported Earnings • Sep 26First half 2024 earnings released: EPS: UK£0.01 (vs UK£0.007 in 1H 2023)First half 2024 results: EPS: UK£0.01 (up from UK£0.007 in 1H 2023). Revenue: UK£21.0m (up 12% from 1H 2023). Net income: UK£4.40m (up 52% from 1H 2023). Profit margin: 21% (up from 15% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.공시 • Sep 24NIOX Group Plc (AIM:NIOX) announces an Equity Buyback for 26,250,000 shares, representing 6.19% for £21 million.NIOX Group Plc (AIM:NIOX) announces a share repurchase program. Under the program, the company will repurchase up to 26,250,000 shares, representing 6.19% of its share capital for £21 million. The shares will be repurchased at £0.8 per share. The company intends to hold 10,000,000 shares in treasury and the remaining shares will be cancelled. The record date for the offer is October 15, 2024. The offer will be valid till October 15, 2024. The tender offer is subject to approval from shareholders in the Extraordinary General Meeting to be held on October 16, 2024. As of September 23, 2024, the company has 424,045,460 shares in issue.공시 • Aug 19NIOX Group Plc to Report First Half, 2024 Results on Sep 24, 2024NIOX Group Plc announced that they will report first half, 2024 results on Sep 24, 2024공시 • Jul 01Niox Group plc Appoints Robert Naylor as Non-Executive Director and Chair of the Audit and Risk CommitteeNIOX Group plc announced the appointment of Robert Naylor, aged 49, as Non-Executive Director and Chair of the Audit and Risk Committee, with immediate effect. Robert has over 25 years' experience in capital markets specialising in healthcare and investment companies and is currently Chief Executive Officer of Intuitive Investments Group plc, an investment company which is quoted on the Specialist Fund Segment of the London Stock Exchange's Main Market, providing investors with exposure to a portfolio of fast-growing technology and life sciences businesses. Additionally, Robert is Non-Executive Chairman of Hipgnosis Songs Fund Limited, a FTSE 250 company, which is currently subject to a recommended cash offer by Lyra Bidco Limited, a newly-formed company indirectly wholly-owned by investment funds advised by affiliates of Blackstone Inc. Previously, Robert was Non-Executive Chairman of Round Hill Music Royalty Fund Limited and oversaw its sale to a company directly owned by Alchemy Copyrights, LLC, trading as Concord. He has also served as a Non-Executive Director of Light Science Technologies Holdings plc, an AIM-quoted controlled environment agriculture company. Earlier in his career Robert held various positions within JP Morgan Asset Management Limited, Panmure Gordon (UK) Limited and Cenkos Securities plc. Robert is a qualified chartered accountant, having started his career with Ernst & Young in 1996. Current directorships/partnerships: Intuitive Investments Group Plc, IIG Assets Ltd, Hipgnosis SFH XX Limited, Hipgnosis SFH XIII Limited, Hipgnosis SFH XIX Limited, Hipgnosis SFH I Limited, Hipgnosis Holdings UK Limited, Rubyruby (London) Limited, Pb Songs Ltd, Kennedy Publishing & Productions Limited, Deamon Limited. Past directorships/partnerships: Round Hill Music Royalty Fund Limited, RHMRF2 Limited, RHMRF3 Limited, Light Science Technologies Holdings plc, Concord Copyrights No.1 Limited (formerly RHMRF1 Limited).Upcoming Dividend • May 16Upcoming dividend of UK£0.01 per shareEligible shareholders must have bought the stock before 23 May 2024. Payment date: 24 June 2024. Trailing yield: 1.4%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (1.7%).공시 • Apr 05NIOX Group Plc Proposes Final Dividend for the Financial Year Ended 31 December 2023, Payable on 24 June 2024NIOX Group Plc announced on 26 March 2024 a proposed final dividend of 1.0 pence per ordinary share in respect of the financial year ended 31 December 2023. The proposed dividend is subject to shareholder approval at the Company's Annual General Meeting ("AGM") to be held on 22 May 2024. Following approval, the dividend will be paid on 24 June 2024 to shareholders on the register at the close of business on the record date of 24 May 2024, with an ex-dividend date of 23 May 2024.Recent Insider Transactions • Mar 31COO & Executive Director recently sold €171k worth of stockOn the 28th of March, Jonathan Emms sold around 234k shares on-market at roughly €0.73 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jonathan's only on-market trade for the last 12 months.Reported Earnings • Mar 26Full year 2023 earnings releasedFull year 2023 results: Revenue: UK£36.8m (up 18% from FY 2022). Net income: UK£9.50m (down 33% from FY 2022). Profit margin: 26% (down from 45% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Germany.공시 • Dec 27+ 1 more updateNIOX Group Plc, Annual General Meeting, May 22, 2024NIOX Group Plc, Annual General Meeting, May 22, 2024.Reported Earnings • Sep 28First half 2023 earnings released: EPS: UK£0.007 (vs UK£0.021 in 1H 2022)First half 2023 results: EPS: UK£0.007 (down from UK£0.021 in 1H 2022). Revenue: UK£18.8m (up 21% from 1H 2022). Net income: UK£2.90m (down 67% from 1H 2022). Profit margin: 15% (down from 57% in 1H 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 42% per year, which means it is significantly lagging earnings growth.New Risk • Sep 27New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 23% Last year net profit margin: 46% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (23% net profit margin).공시 • Jul 21NIOX Group Plc Announces Special Dividend, Payable on 15 September 2023NIOX Group Plc announced a special dividend of 2.5 pence per share (equating to a return of cash of approximately £10.5 million) will be paid on 15 September 2023 to shareholders on the register as at the close of business on Friday 18 August 2023. The Group is now generating sufficient operating cashflow to permit both continued investment in the development of its business and the payment of ongoing dividends to shareholders.공시 • Jun 07NIOX Group Plc Announces Special Dividend, Payable on 15 September 2023NIOX Group Plc announced that a special dividend of 2.5 pence per ordinary share will be paid on 15 September 2023 to shareholders on the register as at 18 August 2023. The associated ex-dividend date will be 17 August 2023.Board Change • Apr 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Non-Independent Non-Executive Director Nick Mills was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Mar 30COO & Executive Director recently sold €114k worth of stockOn the 28th of March, Jonathan Emms sold around 227k shares on-market at roughly €0.50 per share. This transaction amounted to 24% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jonathan's only on-market trade for the last 12 months.Reported Earnings • Mar 22Full year 2022 earnings released: EPS: UK£0.034 (vs UK£0.006 in FY 2021)Full year 2022 results: EPS: UK£0.034 (up from UK£0.006 in FY 2021). Revenue: UK£31.3m (up 12% from FY 2021). Net income: UK£14.1m (up UK£11.8m from FY 2021). Profit margin: 45% (up from 8.2% in FY 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 50% per year, which means it is significantly lagging earnings growth.공시 • Jan 17NIOX Group Plc to Report Fiscal Year 2022 Results on Mar 21, 2023NIOX Group Plc announced that they will report fiscal year 2022 results on Mar 21, 2023Board Change • Oct 31High number of new directorsNon-Independent Non-Executive Director Nick Mills was the last director to join the board, commencing their role in 2020.Reported Earnings • Sep 16First half 2022 earnings released: EPS: UK£0 (vs UK£0.005 loss in 1H 2021)First half 2022 results: EPS: UK£0 (improved from UK£0.005 loss in 1H 2021). Revenue: UK£15.5m (up 6.2% from 1H 2021). Net income: UK£8.90m (up UK£10.9m from 1H 2021). Profit margin: 57% (up from net loss in 1H 2021). The move to profitability was primarily driven by lower expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany.공시 • Jul 14Circassia Group Plc to Report First Half, 2022 Results on Sep 14, 2022Circassia Group Plc announced that they will report first half, 2022 results on Sep 14, 2022Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Non-Executive Director Nick Mills was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공시 • Apr 14Circassia Group Plc, Annual General Meeting, May 13, 2022Circassia Group Plc, Annual General Meeting, May 13, 2022, at 09:00 Coordinated Universal Time. Location: Northbrook House, Robert Robinson Avenue, Oxford Science park Oxford United KingdomRecent Insider Transactions • Apr 02Executive Chairman recently bought €64k worth of stockOn the 29th of March, Ian Johnson bought around 150k shares on-market at roughly €0.43 per share. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of €197k worth in shares.Reported Earnings • Sep 18First half 2021 earnings released: UK£0.005 loss per share (vs UK£0.027 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: UK£14.6m (up 28% from 1H 2020). Net loss: UK£2.00m (loss narrowed 79% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Sep 18Executive Chairman recently bought €65k worth of stockOn the 16th of September, Ian Johnson bought around 150k shares on-market at roughly €0.43 per share. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of €133k worth in shares.공시 • May 27Beyond Air, Inc. Enters into Settlement Agreement with Circassia Group plcOn May 26, 2021, Beyond Air, Inc. entered into a settlement agreement with Circassia Group plc. Under the terms of the Settlement Agreement, the Company retains United States and China commercialization rights to LungFit® PH in exchange for returning $10.5 million in upfront and milestone payments received by the Company in 2019, over a two-year period commencing after the LungFit® PH receives United States Food and Drug Administration approval. Beginning in year three post-approval, Circassia will receive a quarterly royalty payment equal to 5% of LungFit® net sales in the United States, which will terminate once the aggregate payment reaches $6.0 million. The Company now holds full global rights to LungFit® PH.Recent Insider Transactions • Apr 08Executive Chairman recently bought €67k worth of stockOn the 6th of April, Ian Johnson bought around 200k shares on-market at roughly €0.34 per share. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of €120k worth in shares.Reported Earnings • Mar 25Full year 2020 earnings released: UK£0.072 loss per share (vs UK£0.13 loss in FY 2019)The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2020 results: Revenue: UK£23.9m (down 62% from FY 2019). Net loss: UK£26.8m (loss narrowed 45% from FY 2019). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.공시 • Jan 28Circassia Group Plc(AIM:CIR) dropped from FTSE All-Share Index (GBP)Circassia Group Plc(AIM:CIR) dropped from FTSE All-Share Index (GBP)공시 • Nov 13Circassia Group Plc Appoints Nicholas Mills as Non-Executive DirectorCircassia Group Plc announced the appointment of Nicholas Mills as Non-Executive Director, effective 13 November 2020. Nicholas is employed by Harwood Capital LLP. Nicholas joined Harwood Capital LLP in 2019 after spending five years at Gabelli Asset Management in New York. He acted primarily as a Research Analyst covering the multi-industrial space and also gained experience in Merger Arbitrage strategies and marketing Closed End Funds.공시 • Sep 02An unknown buyer acquired 3.4% stake in Circassia Group Plc (AIM:CIR) from CIP Merchant Capital Limited (AIM:CIP) managed by Merchant Capital Manager Limited for £3.9 million.An unknown buyer acquired 3.4% stake in Circassia Group Plc (AIM:CIR) from CIP Merchant Capital Limited (AIM:CIP) managed by Merchant Capital Manager Limited for £3.9 million on September 1, 2020. An unknown buyer completed the acquisition of 3.4% stake in Circassia Group Plc (AIM:CIR) from CIP Merchant Capital Limited (AIM:CIP) managed by Merchant Capital Manager Limited on September 1, 2020.이익 및 매출 성장 예측DB:82C - 애널리스트 향후 추정치 및 과거 재무 데이터 (GBP Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202858102021412/31/202754141919512/31/202650121517512/31/20254971415N/A6/30/20254651718N/A3/31/20254441618N/A12/31/20244231617N/A6/30/202439111213N/A3/31/202438101212N/A12/31/202337101112N/A9/30/20233691111N/A6/30/20233581111N/A3/31/2023331199N/A12/31/2022311477N/A9/30/2022301455N/A6/30/2022291333N/A3/31/202228822N/A12/31/202128211N/A9/30/202128-9-2-2N/A6/30/202127-19-5-5N/A3/31/202126-23-15-14N/A12/31/202024-27-24-24N/A9/30/202026-23-26-25N/A6/30/202027-18-28-26N/A3/31/202031-18-32-26N/A12/31/201935-17-35-25N/A9/30/201937-24N/A-38N/A6/30/201939-32N/A-51N/A3/31/201943-39N/A-46N/A12/31/201848-47N/A-41N/A9/30/201852-50N/A-36N/A6/30/201856-53N/A-31N/A3/31/201851-57N/A-44N/A12/31/201746-60N/A-58N/A6/30/201730-53N/A-54N/A3/31/201727-45N/A-55N/A12/31/201623-37N/A-57N/A9/30/201622-46N/A-63N/A6/30/201621-42N/A-69N/A3/31/201616-46N/A-62N/A12/31/201511-50N/A-56N/A9/30/20156-45N/A-48N/A6/30/20151-40N/A-40N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 82C 의 연간 예상 수익 증가율(17.4%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: 82C 의 연간 수익(17.4%)이 German 시장(16.9%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: 82C 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 82C 의 수익(연간 6%)이 German 시장(연간 6.5%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: 82C 의 수익(연간 6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 82C의 자본 수익률은 3년 후 12.5%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/25 20:26종가2026/06/25 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스NIOX Group Plc는 9명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Julie SimmondsCanaccord GenuityKane SlutzkinDeutsche BankJens LindqvistInvestec Bank plc (UK)6명의 분석가 더 보기
Declared Dividend • May 20Dividend of UK£0.015 announcedShareholders will receive a dividend of UK£0.015. Ex-date: 21st May 2026 Payment date: 22nd June 2026 Dividend yield will be 2.3%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is not adequately covered by earnings (92% earnings payout ratio). However, it is well covered by cash flows (46% cash payout ratio). The dividend has increased by an average of 24% per year over the past 2 years and payments have been stable during that time. The company's earnings per share (EPS) would need to grow by 1.9% to bring the payout ratio under control. EPS is expected to grow by 40% over the next 3 years, which is sufficient to bring the dividend into a sustainable range.
공시 • Apr 22NIOX Group Plc, Annual General Meeting, May 21, 2026NIOX Group Plc, Annual General Meeting, May 21, 2026. Location: the companys registered office magdalen centre, 1 robert robinson ave, the oxford science park, england, ox4 4ga, oxford United Kingdom
공시 • Mar 25Niox Group plc Recommends Final Dividend for the Year Ended 31 December 2025NIOX Group Plc announced that the Board recommended the payment of a final dividend of 1.55 pence per fully paid ordinary share (2024: 1.25 pence). The aggregate amount of the proposed dividend expected to be paid after the reporting date, out of retained earnings at 31 December 2025, but not recognized as a liability at year end is £6.5 million (2024: £5.0 million).
공시 • Mar 20NIOX Group Plc to Report Fiscal Year 2025 Results on Mar 24, 2026NIOX Group Plc announced that they will report fiscal year 2025 results on Mar 24, 2026
공시 • Jul 08NIOX Group Plc to Report First Half, 2025 Results on Sep 30, 2025NIOX Group Plc announced that they will report first half, 2025 results on Sep 30, 2025
공시 • Apr 03Niox Group plc Recommends Final Dividend for the Year Ended December 31, 2024NIOX Group Plc recommended final dividend of 1.25 pence per share in respect of the year ended December 31 2024.
공시 • Mar 21An unknown funds managed by Keensight Capital made a proposal to acquire NIOX Group Plc (AIM:NIOX) for approximately £320 million.An unknown funds managed by Keensight Capital made a proposal to acquire NIOX Group Plc (AIM:NIOX) for approximately £320 million on February 20, 2025. As on March 6, 2025, The Board of NIOX Group received a revised proposal from Keensight Capital on behalf of funds managed or advised by it ("Keensight") regarding a possible cash offer to acquire the entire issued and to be issued ordinary share capital of NIOX (the "Proposal") at an offer price of £0.81 per NIOX share, the Proposal follows a previous unsolicited approach by Keensight to acquire NIOX on February 20, 2025 at an offer price of £0.78 per NIOX share. The Proposal is subject to the satisfaction or waiver by Keensight of a number of pre-conditions, including the completion of satisfactory due diligence. Accordingly, the Board has agreed to provide Keensight with access to due diligence. Discussions with Keensight remain at a preliminary stage and, as such, there can be no certainty that any firm offer will be made for the Company by Keensight, nor as to the terms of any such offer, should one be made. Lazard & Co., Limited and Singer Capital Markets Advisory LLP acted as financial advisor to NIOX.
공시 • Jan 17NIOX Group Plc, Annual General Meeting, May 14, 2025NIOX Group Plc, Annual General Meeting, May 14, 2025.
공시 • Jan 16+ 1 more updateNIOX Group Plc Appoints Jonathan Emms as Chief Executive OfficerNIOX Group Plc announced Jonathan Emms, currently Chief Operating Officer, has been appointed Chief Executive Officer with immediate effect.
공시 • Dec 04NIOX Group Plc to Report Fiscal Year 2024 Results on Apr 01, 2025NIOX Group Plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Apr 01, 2025
Reported Earnings • Sep 26First half 2024 earnings released: EPS: UK£0.01 (vs UK£0.007 in 1H 2023)First half 2024 results: EPS: UK£0.01 (up from UK£0.007 in 1H 2023). Revenue: UK£21.0m (up 12% from 1H 2023). Net income: UK£4.40m (up 52% from 1H 2023). Profit margin: 21% (up from 15% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
공시 • Sep 24NIOX Group Plc (AIM:NIOX) announces an Equity Buyback for 26,250,000 shares, representing 6.19% for £21 million.NIOX Group Plc (AIM:NIOX) announces a share repurchase program. Under the program, the company will repurchase up to 26,250,000 shares, representing 6.19% of its share capital for £21 million. The shares will be repurchased at £0.8 per share. The company intends to hold 10,000,000 shares in treasury and the remaining shares will be cancelled. The record date for the offer is October 15, 2024. The offer will be valid till October 15, 2024. The tender offer is subject to approval from shareholders in the Extraordinary General Meeting to be held on October 16, 2024. As of September 23, 2024, the company has 424,045,460 shares in issue.
공시 • Aug 19NIOX Group Plc to Report First Half, 2024 Results on Sep 24, 2024NIOX Group Plc announced that they will report first half, 2024 results on Sep 24, 2024
공시 • Jul 01Niox Group plc Appoints Robert Naylor as Non-Executive Director and Chair of the Audit and Risk CommitteeNIOX Group plc announced the appointment of Robert Naylor, aged 49, as Non-Executive Director and Chair of the Audit and Risk Committee, with immediate effect. Robert has over 25 years' experience in capital markets specialising in healthcare and investment companies and is currently Chief Executive Officer of Intuitive Investments Group plc, an investment company which is quoted on the Specialist Fund Segment of the London Stock Exchange's Main Market, providing investors with exposure to a portfolio of fast-growing technology and life sciences businesses. Additionally, Robert is Non-Executive Chairman of Hipgnosis Songs Fund Limited, a FTSE 250 company, which is currently subject to a recommended cash offer by Lyra Bidco Limited, a newly-formed company indirectly wholly-owned by investment funds advised by affiliates of Blackstone Inc. Previously, Robert was Non-Executive Chairman of Round Hill Music Royalty Fund Limited and oversaw its sale to a company directly owned by Alchemy Copyrights, LLC, trading as Concord. He has also served as a Non-Executive Director of Light Science Technologies Holdings plc, an AIM-quoted controlled environment agriculture company. Earlier in his career Robert held various positions within JP Morgan Asset Management Limited, Panmure Gordon (UK) Limited and Cenkos Securities plc. Robert is a qualified chartered accountant, having started his career with Ernst & Young in 1996. Current directorships/partnerships: Intuitive Investments Group Plc, IIG Assets Ltd, Hipgnosis SFH XX Limited, Hipgnosis SFH XIII Limited, Hipgnosis SFH XIX Limited, Hipgnosis SFH I Limited, Hipgnosis Holdings UK Limited, Rubyruby (London) Limited, Pb Songs Ltd, Kennedy Publishing & Productions Limited, Deamon Limited. Past directorships/partnerships: Round Hill Music Royalty Fund Limited, RHMRF2 Limited, RHMRF3 Limited, Light Science Technologies Holdings plc, Concord Copyrights No.1 Limited (formerly RHMRF1 Limited).
Upcoming Dividend • May 16Upcoming dividend of UK£0.01 per shareEligible shareholders must have bought the stock before 23 May 2024. Payment date: 24 June 2024. Trailing yield: 1.4%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (1.7%).
공시 • Apr 05NIOX Group Plc Proposes Final Dividend for the Financial Year Ended 31 December 2023, Payable on 24 June 2024NIOX Group Plc announced on 26 March 2024 a proposed final dividend of 1.0 pence per ordinary share in respect of the financial year ended 31 December 2023. The proposed dividend is subject to shareholder approval at the Company's Annual General Meeting ("AGM") to be held on 22 May 2024. Following approval, the dividend will be paid on 24 June 2024 to shareholders on the register at the close of business on the record date of 24 May 2024, with an ex-dividend date of 23 May 2024.
Recent Insider Transactions • Mar 31COO & Executive Director recently sold €171k worth of stockOn the 28th of March, Jonathan Emms sold around 234k shares on-market at roughly €0.73 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jonathan's only on-market trade for the last 12 months.
Reported Earnings • Mar 26Full year 2023 earnings releasedFull year 2023 results: Revenue: UK£36.8m (up 18% from FY 2022). Net income: UK£9.50m (down 33% from FY 2022). Profit margin: 26% (down from 45% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Germany.
공시 • Dec 27+ 1 more updateNIOX Group Plc, Annual General Meeting, May 22, 2024NIOX Group Plc, Annual General Meeting, May 22, 2024.
Reported Earnings • Sep 28First half 2023 earnings released: EPS: UK£0.007 (vs UK£0.021 in 1H 2022)First half 2023 results: EPS: UK£0.007 (down from UK£0.021 in 1H 2022). Revenue: UK£18.8m (up 21% from 1H 2022). Net income: UK£2.90m (down 67% from 1H 2022). Profit margin: 15% (down from 57% in 1H 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 42% per year, which means it is significantly lagging earnings growth.
New Risk • Sep 27New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 23% Last year net profit margin: 46% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (23% net profit margin).
공시 • Jul 21NIOX Group Plc Announces Special Dividend, Payable on 15 September 2023NIOX Group Plc announced a special dividend of 2.5 pence per share (equating to a return of cash of approximately £10.5 million) will be paid on 15 September 2023 to shareholders on the register as at the close of business on Friday 18 August 2023. The Group is now generating sufficient operating cashflow to permit both continued investment in the development of its business and the payment of ongoing dividends to shareholders.
공시 • Jun 07NIOX Group Plc Announces Special Dividend, Payable on 15 September 2023NIOX Group Plc announced that a special dividend of 2.5 pence per ordinary share will be paid on 15 September 2023 to shareholders on the register as at 18 August 2023. The associated ex-dividend date will be 17 August 2023.
Board Change • Apr 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Non-Independent Non-Executive Director Nick Mills was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Mar 30COO & Executive Director recently sold €114k worth of stockOn the 28th of March, Jonathan Emms sold around 227k shares on-market at roughly €0.50 per share. This transaction amounted to 24% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jonathan's only on-market trade for the last 12 months.
Reported Earnings • Mar 22Full year 2022 earnings released: EPS: UK£0.034 (vs UK£0.006 in FY 2021)Full year 2022 results: EPS: UK£0.034 (up from UK£0.006 in FY 2021). Revenue: UK£31.3m (up 12% from FY 2021). Net income: UK£14.1m (up UK£11.8m from FY 2021). Profit margin: 45% (up from 8.2% in FY 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 50% per year, which means it is significantly lagging earnings growth.
공시 • Jan 17NIOX Group Plc to Report Fiscal Year 2022 Results on Mar 21, 2023NIOX Group Plc announced that they will report fiscal year 2022 results on Mar 21, 2023
Board Change • Oct 31High number of new directorsNon-Independent Non-Executive Director Nick Mills was the last director to join the board, commencing their role in 2020.
Reported Earnings • Sep 16First half 2022 earnings released: EPS: UK£0 (vs UK£0.005 loss in 1H 2021)First half 2022 results: EPS: UK£0 (improved from UK£0.005 loss in 1H 2021). Revenue: UK£15.5m (up 6.2% from 1H 2021). Net income: UK£8.90m (up UK£10.9m from 1H 2021). Profit margin: 57% (up from net loss in 1H 2021). The move to profitability was primarily driven by lower expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany.
공시 • Jul 14Circassia Group Plc to Report First Half, 2022 Results on Sep 14, 2022Circassia Group Plc announced that they will report first half, 2022 results on Sep 14, 2022
Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Non-Executive Director Nick Mills was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공시 • Apr 14Circassia Group Plc, Annual General Meeting, May 13, 2022Circassia Group Plc, Annual General Meeting, May 13, 2022, at 09:00 Coordinated Universal Time. Location: Northbrook House, Robert Robinson Avenue, Oxford Science park Oxford United Kingdom
Recent Insider Transactions • Apr 02Executive Chairman recently bought €64k worth of stockOn the 29th of March, Ian Johnson bought around 150k shares on-market at roughly €0.43 per share. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of €197k worth in shares.
Reported Earnings • Sep 18First half 2021 earnings released: UK£0.005 loss per share (vs UK£0.027 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: UK£14.6m (up 28% from 1H 2020). Net loss: UK£2.00m (loss narrowed 79% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Sep 18Executive Chairman recently bought €65k worth of stockOn the 16th of September, Ian Johnson bought around 150k shares on-market at roughly €0.43 per share. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of €133k worth in shares.
공시 • May 27Beyond Air, Inc. Enters into Settlement Agreement with Circassia Group plcOn May 26, 2021, Beyond Air, Inc. entered into a settlement agreement with Circassia Group plc. Under the terms of the Settlement Agreement, the Company retains United States and China commercialization rights to LungFit® PH in exchange for returning $10.5 million in upfront and milestone payments received by the Company in 2019, over a two-year period commencing after the LungFit® PH receives United States Food and Drug Administration approval. Beginning in year three post-approval, Circassia will receive a quarterly royalty payment equal to 5% of LungFit® net sales in the United States, which will terminate once the aggregate payment reaches $6.0 million. The Company now holds full global rights to LungFit® PH.
Recent Insider Transactions • Apr 08Executive Chairman recently bought €67k worth of stockOn the 6th of April, Ian Johnson bought around 200k shares on-market at roughly €0.34 per share. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of €120k worth in shares.
Reported Earnings • Mar 25Full year 2020 earnings released: UK£0.072 loss per share (vs UK£0.13 loss in FY 2019)The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2020 results: Revenue: UK£23.9m (down 62% from FY 2019). Net loss: UK£26.8m (loss narrowed 45% from FY 2019). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
공시 • Jan 28Circassia Group Plc(AIM:CIR) dropped from FTSE All-Share Index (GBP)Circassia Group Plc(AIM:CIR) dropped from FTSE All-Share Index (GBP)
공시 • Nov 13Circassia Group Plc Appoints Nicholas Mills as Non-Executive DirectorCircassia Group Plc announced the appointment of Nicholas Mills as Non-Executive Director, effective 13 November 2020. Nicholas is employed by Harwood Capital LLP. Nicholas joined Harwood Capital LLP in 2019 after spending five years at Gabelli Asset Management in New York. He acted primarily as a Research Analyst covering the multi-industrial space and also gained experience in Merger Arbitrage strategies and marketing Closed End Funds.
공시 • Sep 02An unknown buyer acquired 3.4% stake in Circassia Group Plc (AIM:CIR) from CIP Merchant Capital Limited (AIM:CIP) managed by Merchant Capital Manager Limited for £3.9 million.An unknown buyer acquired 3.4% stake in Circassia Group Plc (AIM:CIR) from CIP Merchant Capital Limited (AIM:CIP) managed by Merchant Capital Manager Limited for £3.9 million on September 1, 2020. An unknown buyer completed the acquisition of 3.4% stake in Circassia Group Plc (AIM:CIR) from CIP Merchant Capital Limited (AIM:CIP) managed by Merchant Capital Manager Limited on September 1, 2020.